Background {#Sec1}
==========

In recent years a range of efforts and new initiatives have been implemented across Europe to increase Human Immunodeficiency Virus (HIV) testing among key populations and to reduce the number of undiagnosed HIV infections and late diagnoses \[[@CR1]\]. Despite some progress in terms of increased testing uptake, a recent report from the European Centre for Disease Prevention and Control (ECDC) estimates that the proportion of undiagnosed HIV among Men having Sex with Men (MSM) in six European countries is 17% \[[@CR2]\]. This falls short of the internationally agreed goal of diagnosing at least 90% of the people who are infected \[[@CR3]\]. Furthermore, approximately one third of HIV diagnoses among MSM in the European Union (EU) are late (CD4 \< 350 cells/μl at diagnosis). Reducing late HIV diagnoses would result in substantial individual (i.e. reduced morbidity and mortality) and public health benefits (reduced transmission and reduction of health care costs) \[[@CR4], [@CR5]\]. In addition to adverse health outcomes, late diagnoses and late initiation of antiretroviral therapy are associated with increased risks for transmitting HIV unknowingly to sexual partners.

In countries with unrestricted access to antiretroviral treatment undiagnosed HIV infections are thought to be the main sources of new HIV infections. Early diagnosis of HIV and successful treatment are thus important for the successful management of the disease in individual patients as well as major tools supporting the implementation of the WHO strategy for anti-retroviral treatment as prevention \[[@CR3], [@CR6], [@CR7]\].

The level of undiagnosed infections is driven by HIV incidence on the one hand and by the testing rate on the other. Factors increasing HIV incidence are likely to contribute to the increased level of undiagnosed infections, even among frequent testers. Additionally, barriers to testing and low testing uptake may cause accumulation of infections, including late stage infections \[[@CR8], [@CR9]\].

Little is known about the characteristics and sexual behaviours of people with undiagnosed infections. Some information can be retrieved from HIV testing sites from people newly diagnosed with HIV \[[@CR10]--[@CR12]\], although the demographic data collected and analysed are quite limited from such clinical sites \[[@CR13], [@CR14]\]. People presenting for testing self-select and therefore such samples may be biased. Another way to collect such information is from longitudinal cohort studies including HIV-uninfected people at risk for HIV. However, such studies are time consuming, costly, and rarely conducted in Europe. In addition, participants may not be representative of the population at risk in real world settings. Bio-behavioural studies, such as the multi-city Sialon II study, may therefore be better suited to systematically collect information on people who are unknowingly infected with HIV \[[@CR15], [@CR16]\] with more scientific rigour and fewer biases.

In general, the risk of HIV infection among MSM is associated with sexual risk practices such as the lack of condom use, number of partners with whom condomless anal intercourse is practised, drug use associated with sex, and attending gay sex venues where risky sexual behaviours are part of the sub-culture \[[@CR17]\]. However, such risk practices are driven by a complex set of intertwined factors, ranging from the personal level factors (e.g. age, personal skills and self-efficacy, mental health) to interpersonal factors (partner dynamics, communication and negotiation on sex practices), to community and service provision-related factors (social and sexual norms, perceived homonegativity in communities; access to testing and other medical services) and structural factors (policies and legislation). The intersection of these factors is further shaped by high HIV prevalence in subgroups of MSM \[[@CR18]\].

Barriers to HIV testing have also been extensively described in the literature: testing for HIV is more likely for individuals who perceive themselves at risk for HIV and who anticipate personal benefits from testing, while fears of consequences of receiving an HIV diagnosis hinders HIV testing. The latter has been shown to be associated with fear of discrimination and personal rejection \[[@CR19], [@CR20]\]. Research has also shown that multiple social-cognitive factors (e.g. knowledge, attitudes, perceived behavioural control) play a role in explaining testing for HIV and sexually transmitted infections (STI) among MSM \[[@CR20]\]. In addition to patient-level factors, a review demonstrated the influence of health-systems and structural factors on uptake of HIV testing \[[@CR8]\].

The present study used data from a large multi-city European bio-behavioural survey conducted among MSM within the framework of the European Public Health Project Sialon II. The analysis has two objectives -- 1) to identify factors correlating with early undiagnosed infections among testers, which are most likely driven by HIV incidence among repeat testers; and 2) to characterise groups that are not adhering to testing recommendations in order to properly inform appropriate testing campaigns targeted towards them.

Methods {#Sec2}
=======

Study design and procedures {#Sec3}
---------------------------

Sialon II was a multi-site bio-behavioural cross-sectional survey carried out in 13 European cities*.* The cities were: Brussels (Belgium), Sofia (Bulgaria), Hamburg (Germany), Verona (Italy), Vilnius (Lithuania), Warsaw (Poland), Lisbon (Portugal), Bucharest (Romania), Bratislava (Slovakia), Ljubljana (Slovenia), Barcelona (Spain), Stockholm (Sweden), and Brighton (UK). In 2013/2014, MSM were recruited to participate in the survey using time-location-sampling (TLS) in community-based settings in nine European cities, and using respondent-driven-sampling (RDS) in social networks of MSM in four European cities (Bucharest, Bratislava, Verona, Vilnius). In TLS cities participants were recruited during 2013, in RDS cities recruitment started in 2013 and finished in 2014. Recruitment methods, study procedures, questions asked as well as sample collection and testing have been described in detail elsewhere \[[@CR21]\]. The study protocol was approved by ethical review committees in all participating countries and by the WHO Research Project Review Panel (WHO-RP2) and the WHO Research Ethics Review Committee (WHO-ERC) before the data collection phase.

The bio-behavioural survey data generated from the Sialon II project provided the opportunity to combine data on testing history and self-reported HIV test result, and to link them with the laboratory determined HIV status to identify men with an undiagnosed HIV infection at the time of the survey implementation. In this analysis, sexual behaviours and social characteristics of these men with undiagnosed HIV infection are assessed and compared with their uninfected peers.

Measures {#Sec4}
--------

Participants filled in a short questionnaire and provided either an oral fluid (in TLS cities) or blood (in RDS cities) specimen for HIV antibody testing. Based on self-reported HIV status and the HIV testing result of the collected specimen, participants were classified as HIV-uninfected (nHIV), previously diagnosed with HIV infection (pHIV), and HIV-infected but as yet undiagnosed (uHIV). As far as the time of HIV diagnosis is concerned, three different patterns can be distinguished: 1) early diagnosis, when testing is predominantly triggered by symptoms of acute HIV infection and/or awareness of transmission risk; 2) intermediate diagnosis, when testing is triggered by health concerns not immediately related to acute HIV disease or transmission risk awareness; 3) late diagnosis, often triggered by symptoms or health complaints associated with compromised immune status. These three patterns may be associated with different demographic and behavioural characteristics (see below). Since data on HIV testing intentions were not collected, we used HIV testing history to distinguish between a group with likely high testing frequency and incident HIV infection (uHIVinc - negative test result reported within 12 months before the study specimen was collected) and MSM who were tested a longer time ago or never tested for HIV infection of unknown onset (uHIVunk). The uHIVinc subgroup may represent pattern 1 and partially pattern 2 testers, while the uHIVunk subgroup may represent the complementary part of pattern 2 and pattern 3 testers.

The following questionnaire items were used to determine if the case had been previously diagnosed: a question whether and if yes, when the last HIV antibody test was performed and a question on the result of the last HIV antibody test. If these questions were not answered or information was inconsistent HIV status knowledge was classified as undetermined and respondents were excluded from the analysis. In addition, participants recruited in Sofia had to be excluded from the two test recency subgroup analyses because the answers were invalid due to an incorrect translation of the respective question.

Lab testing of biological samples {#Sec5}
---------------------------------

In line with the TLS protocols, oral fluid (OF) specimens were collected and tested for HIV antibodies using Genscreen HIV 1/2 version 2, BIO-RAD. A total IgG antibodies ELISA test Human IgG ELISA Kit 1 × 96, Quantitative / Immunology Consultants Laboratory was used for OF specimen testing suitability and quality control. All HIV-reactive specimens were re-tested with Vironostika HIV Ag/Ab, bioMérieux. Specimens tested positive with the first HIV ELISA test, but negative with the second were classified as negative.

MSM who participated to the survey in cities where RDS was used as recruitment method received pre/post-test counselling during the enrolment and follow up process. Blood samples were collected and serum extracted in line with the local standard procedures. Serum samples were tested with an HIV 4th generation ELISA/CLIA screening test. A Western blot test was used to confirm positive cases. In case of a confirmed HIV positive result, a referral procedure was put in place in line with the local standard procedures to ensure linkage to care and proper case management.

Secondary variables {#Sec6}
-------------------

Based on published literature on factors associated with HIV acquisition risk, undiagnosed HIV infection or infrequent HIV testing and late diagnosis among MSM (as mentioned in the introduction), associations of uHIV, uHIVinc and uHIVunk status were analysed with:Demographic variables such as age (calculated using the self-reported year of birth), education level (secondary school or lower, high school or post-secondary or university/ higher), migration status (native: born & living in the study country; emigrant: born in the study country & living abroad; immigrant: born abroad & living in the study country; visitor: born & living abroad);Behavioural variables such as number of sexual partners and number of partners with whom condomless anal intercourse (AI) had been practiced in the previous 6 months, frequency of visiting gay sex venues in the last 3 months, type and number of drugs used during last AI (categorised as alcohol; cannabis; sexual performance enhancing substances: erectile dysfunction medication and inhaled amyl nitrite; party drugs: cocaine, ecstasy, amphetamines; chemsex drugs: GHB, ketamine, mephedrone, crystal meth);Type of partners for last AI (steady, non-steady, more than one), self-reported HIV serostatus disclosure to the last AI partner, sexual role during last AI (top, bottom, versatile), condom use during last AI;HIV and STI testing in the previous 12 months, and "outness" about sexual orientation towards relatives, friends, and co-workers.

The self-administered questionnaire filled-in by the study participants is available as Additional file [1](#MOESM1){ref-type="media"}.

Statistical analysis {#Sec7}
--------------------

We conducted analyses of bivariate and multivariate associations of explanatory variables with uHIV, and the two subgroups uHIVinc and uHIVunk, using nHIV for comparison. For the two subgroups, the comparison group was also determined by their last reported HIV test date, i.e. the comparison group for uHIVinc was tested negative within the previous 12 months, and the comparison group for uHIVunk was never tested or tested more than 12 months ago.

A multivariate multi-level logistic random-intercept model (random effect of study site) was estimated to account for the hierarchical structure of the data \[[@CR22]\]. The multi-level analysis was conducted to identify factors associated with each subgroup separately and with the combined group. Predictors associated with the outcome variable with a probability \< 0.05 were considered significant.

Stata Version 14.2 was used (College Station, TX: StataCorp LP).

The dataset used for the analysis presented in this manuscript is available as Additional file [2](#MOESM2){ref-type="media"}. The Stata syntax of the analysis is available as Additional file [3](#MOESM3){ref-type="media"}.

Results {#Sec8}
=======

Study sample {#Sec9}
------------

A detailed description of the study sample has been published in the study report \[[@CR23]\]. At most study sites, approximately 400 men had been recruited as requested by the study protocol, with exception of Bucharest, where only 183 participants were enrolled. There were significant age differences between study sites. The proportion of study participants tested for HIV in the last 12 months before completing the study questionnaire among those not known to have been diagnosed with HIV ranged between 35.5% in Bratislava and 66.2% in Barcelona (see Table [1](#Tab1){ref-type="table"}).Table 1Sialon II study participants by study site, testing history and measured HIV status after exclusion of participants already known to have HIV and with indeterminate HIV status knowledgecityHIV negative (n)percentage tested for HIV in the last 12 months (%)undiagnosed HIV infection (n)percentage with undiagnosed HIV (%)undiagnosed HIV, negative HIV pre-test within recent 12 months (n)undiagnosed HIV infection, no pre-test or test longer ago than 12 months (n)percentage of undiagnosed HIV that may not be recent (%)Total (N)Barcelona33466.2%215.9%16523.8%355Bratislava37635.5%153.8%6960.0%391Brighton33156.7%154.3%10533.3%346Brussels32763.5%72.1%5228.6%334Bucharest14642.9%159.3%7853.3%161Hamburg33652.1%154.3%11426.7%351Lisbon30063.8%298.8%23620.7%329Ljubljana32950.9%72.1%5228.6%336Sofia^a^344123.4%356Stockholm33449.9%30.9%2133.3%337Verona36741.9%102.7%2880.0%377Vilnius31438.9%51.6%2360.0%319Warsaw34657.9%226.0%17522.7%368Total41841764.0%4360Total w/o Sofia384051.9%1641065833.0%4004^a^data on recency of last HIV testing are missing for Sofia due to incorrect translation of the question in the Bulgarian questionnaire version

Formative research conducted in preparation of the bio-behavioural survey established that HIV testing sites, including sites providing free and anonymous HIV testing and rapid testing existed in all study cities at the time when study recruitment occurred \[[@CR24]\]. Further qualitative assessments of gay-friendliness, accessibility and acceptability of available testing services were not conducted. HIV home tests and home collection tests were unavailable.

A valid HIV test result was available for 4716 participants. The antibody test result was non-reactive for 4219 specimens, and reactive for 497 specimens (11.8%). From the 4219 participants with non-reactive specimens 4184 (99%) were classified as nHIV, 35 were classified as indeterminate due to conflicting or missing self-reported data on HIV infection status. From the participants with reactive specimens 234 (47%) were classified as pHIV, 102 (20.5%) as uHIVinc, and 49 (9.9%) as uHIVunk based on self-reported infection status and testing history. Twelve participants from Sofia with undiagnosed HIV infection could not be classified in these two subgroups. The remaining 100 (20.1%) participants with reactive specimens had to be classified as indeterminate based on questionnaire data due to incomplete information on testing history and status knowledge (e.g. non-response to the question on previous HIV test and/or test result).

A weak positive correlation between the percentage of the participants tested for HIV by study site in the recent 12 months and the percentage of undiagnosed HIV in the study sites was observed (*r* = .275 - see Table [1](#Tab1){ref-type="table"}).

Undiagnosed HIV infections and associations with demographics and behaviours {#Sec10}
----------------------------------------------------------------------------

The distribution of all and of undiagnosed infections by age group is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Age distribution and prevalence of HIV infection and undiagnosed HIV by age group in the Sialon II participants, Sialon II biobehavioural survey, 2013--2014

The percentage of undiagnosed infections from all prevalent infections is approaching 50% in age groups younger than 35 years-old and declines to less than 30% in older age groups.

Table [1](#Tab1){ref-type="table"} shows the distribution of undiagnosed HIV infections by study sites. The proportion of study participants with undiagnosed HIV infection ranged from 0.9% in Stockholm to 9.3% in Bucharest. The overall proportion of undiagnosed HIV infections among men without a recent test result was almost one-third of the undiagnosed infections, ranging from 20.7% in Lisbon to 80% in Verona. The proportions of undiagnosed HIV among infrequent testers were consistently higher than 50% in the four cities Bratislava, Bucharest, Vilnius and Verona, in which RDS was used for recruitment.

Table [2](#Tab2){ref-type="table"} shows the reported last test dates among study participants who did not report having HIV or a last HIV test within the 12 months before they were recruited to the Sialon study.Table 2Distribution of Sialon II study participants who were not aware of having HIV by laboratory-determined HIV status and year of last HIV test - overall and by test recency groupuHIV - study sampleuHIVunk - last HIV test not within 12 months of recruitment into the studyYear of last reported testHIV negativeHIV positive, undiagnosedYear of last reported testHIV negativeHIV positive, undiagnosed198710198710198810198810198920198920199050199050199110199110199230199230199320199320199410199410199541199541199621199621199751199751199870199870199960199960200018020001802001100200110020021312002131200315020031502004140200414020053922005392200622220062222007390200739020086102008610200980420098042010151132010151132011267820112678201278547201220510201313067020133022014320never tested/year missing86413year missing^a^129226Total186858Total4184176uHIVinc - last test within 12 months before recruitment into the study20125803720131276682014320year missing, test within the last 12 months reported841Total1972106^a^includes 356 participants from Sofia whose last HIV test date could not be determined

Table [3](#Tab3){ref-type="table"} shows results of bivariate analysis of associations between potential explanatory variables and the outcomes 1) undiagnosed HIV infection, acquired within the previous 12 months - uHIVinc; 2) undiagnosed HIV infection of unknown onset - uHIVunk; 3) undiagnosed HIV infection irrespective of date of previous HIV test (1 and 2 combined - uHIV).Table 3Associations between demographic and behaviour variables and undiagnosed HIV infection in participants of the European Sialon II biobehavioural surveyuHIVincuHIVunkuHIVNOdds Ratio*p*-value\[95% Conf. Interval\]Odds Ratio*p*-value\[95% Conf. Interval\]Odds Ratio*p*-value\[95% Conf. Interval\]Age group18--24ref.92325--34**3.340.00**1.587.071.690.250.704.07**2.650.00**1.564.50173035--44**3.050.01**1.376.80**2.820.02**1.186.73**2.900.00**1.665.0697045--542.370.070.945.972.000.190.725.59**2.160.02**1.114.1948855+1.360.660.355.201.390.640.355.461.340.540.523.44244Migration statusnativeref.3565emigrant2.140.200.637.20**6.780.02**1.4531.84**3.060.01**1.297.2754immigrant1.030.920.581.811.320.480.612.831.170.490.751.84503visitor: born & live abroad0.700.450.281.961.780.730.193.260.780.530.361.69226Any STI test in last 12 monthsnoref.2249yes1.150.620.671.95**3.01**0.001.565.84**1.940.00**1.422.662007STI diagnosesno diagnosisref.39461 diagnosis0.710.360.341.48**6.310.00**2.1018.051.240.430.722.143102 diagnoses1.030.970.313.354.960.140.6041.011.400.520.503.88743 diagnoses1.070.950.148.101.00------1.440.730.1910.88184 diagnoses1.00------1.00------1.00------85 diagnoses6.040.120.6258.661.00------8.150.070.8478.824any STI diagnosis0.820.520.461.49**5.980.00**2.2316.061.310.260.822.09414Number of sex partnersno partnerref.2691 partner0.640.380.241.724.820.130.6237.341.370.460.593.178192--3 partners0.780.590.311.963.730.210.4729.341.340.480.593.079814--5 partners0.790.630.302.084.570.160.5637.451.490.360.643.516266--10 partners0.670.430.251.80**8.350.04**1.0864.421.620.260.703.73701\> 10 partners0.990.890.402.47**10.210.03**1.3079.90**2.280.05**1.015.14748Number of partners with condomless anal intercourseno partnerref.14991 partner0.570.060.321.021.300.540.572.960.850.490.551.3311082--3 partners1.130.650.671.90**2.110.07**0.954.681.360.160.892.078394--5 partners0.670.460.241.92**5.030.00**1.9213.161.500.220.792.852356--10 partners1.170.750.453.052.940.100.8010.671.790.090.923.50182\> 10 partners**2.680.02**1.146.30**12.840.00**3.7543.93**3.550.00**1.836.88106Type of partners in last 6 monthssteady partner(s)ref.653non-steady partner(s)1.180.650.582.381.080.860.492.351.120.660.681.851297s + ns partner(s)1.310.420.682.551.001.000.492.041.230.390.771.972001no partner1.670.350.564.970.220.150.031.710.780.600.311.95216Anal sex in last 6 monthsno anal sexref.857anal intercourse (with condom)0.870.650.471.591.210.670.502.951.120.650.691.841005condomless anal intercourse0.800.430.471.38**1.950.05**0.993.851.300.210.861.982498Type of partner at last anal sexsteady partnerref.1880non-steady partner1.010.960.651.671.040.070.953.171.300.130.931.821760more than one partner**2.060.04**1.034.112.330.130.777.04**2.220.01**1.243.97207Sexual role with last AI partnertopref.1324bottom1.110.710.641.941.070.930.491.940.980.930.651.481265versatile**2.080.00**1.273.421.001.000.482.09**1.610.02**1.092.371035Serostatus disclosure to last AI partnerno disclosureref.2400disclosure**0.270.00**0.150.481.180.820.562.06**0.500.00**0.330.751262Number of drugs consumed at last anal sex0ref.19591**2.310.00**1.373.910.910.750.501.66**1.500.03**1.042.1613942**2.980.00**1.585.610.990.990.412.42**1.740.02**1.082.795163**4.300.00**2.039.091.00------**2.310.01**1.194.491674**5.590.00**1.7911.802.040.500.2615.97**3.330.00**1.467.55765**4.690.02**1.3216.701.00------2.660.110.808.87406**9.380.01**1.8954.647.660.070.8370.60**8.190.00**2.2529.821574.170.180.5134.291.00------2.980.300.3823.461281.00------1.00------1.00------69**18.760.02**1.64214.371.00------**10.930.04**1.12106.624Type of drugsno party drugref.3875party**2.900.00**1.774.770.360.320.052.66**2.040.00**1.293.22307no chemsex drugref.4063chemsex**2.140.04**1.044.391.890.540.2514.45**2.420.01**1.244.71111no sexual performance substanceref.3326sexual performance substance**2.410.00**1.613.611.790.070.953.37**2.150.00**1.552.98853no cannabisref.3869cannabis**2.200.01**1.273.790.890.850.272.91**1.750.02**1.082.83304no alcoholref.2.324alcohol**1.900.00**1.262.840.700.230.401.251.330.070.981.801859Satisfaction with sex lifeunsatisfiedref.950satisfied1.700.080.943.081.160.670.592.271.480.060.982.223.124

Compared with HIV uninfected survey participants, men assigned to the uHIVinc group were more likely to be 25--44 years of age (compared to the reference age group 18--24), and showed higher odds for the use of drugs during last anal sex, they were less likely to have disclosed their presumed negative HIV serostatus to their last anal sex partner(s), more likely to have been versatile during their last anal sex encounter, and more likely to have had more than 10 partners in the last 6 months with whom they had condomless anal intercourse.

Men assigned to the uHIVunk group were more likely to be older (age groups 35--44) than HIV-uninfected men who had not been tested for HIV in the last 12 months, to report any condomless anal intercourse in the last 6 months, and to have higher numbers of partners in the last 6 months with whom they had condomless anal sex, they were more likely to have been tested for and diagnosed with an STI in the last 12 months, and more likely to be an emigrant on home visit to his country of origin, but they were mostly inconspicuous in terms of substance use and most other potential explanatory variables.

In multivariate analysis assignment to the uHIVinc group remained significantly associated with age 25--34, and versatility, lack of serostatus disclosure, and use of party and sexual performance enhancing drugs during the last anal sex event (see Table [4](#Tab4){ref-type="table"}). The only factors remaining associated with uHIVunk in multivariate analysis were age 35--54, higher number of partners with whom condomless anal sex had been practiced in the last 6 months, and more frequent STI testing in the last 12 months.Table 4Multivariate multilevel models to estimate associations between undiagnosed^a^ HIV infection and demographic and behavioural parameters among participants of the Sialon II studyOdds Ratio*p*-value\[95% Conf. Interval\]uHIVinc (*n* = 1713) Age group18--24ref.25--34**2.270.04**1.034.9935--441.620.290.673.9045--541.370.560.483.9655+1.080.910.264.46 Sexual role with last AI partnertopref.bottom1.120.730.602.07versatile**2.050.01**1.183.55 Type of drugs during last anal sexno use of ecstasy, cocaine, amphetamineref.ecstasy, cocaine, amphetamine**2.220.02**1.174.21no use of sexual performance substances (poppers, erectile dysfunction medication)ref.sexual performance substances (poppers, erectile dysfunction medication)**1.960.01**1.173.28 Serostatus disclosure to last AI partnerdisclosureref.no disclosure**3.940.00**2.147.27 \_cons*0.010.000.000.01* city*0.40--0.111.45*uHIVunk (*n* = 1639) Age group18--24ref.25--342.000.160.765.2735--44**3.730.01**1.419.8445--54**3.310.04**1.0810.1255+0.900.930.107.84 Number of partners with condomless anal intercourseno partnerref.1 partner1.460.380.633.362--3 partners**2.660.02**1.176.044--5 partners**6.080.00**2.2616.406--10 partners2.010.380.439.44\> 10 partners**12.830.00**3.6045.65 STI testing in last 12 monthsno testingref.any STI testing**3.610.00**1.747.50 \_cons*0.020.000.010.07* city*0.00------*uHIV (*n* = 3745) Age group18--24ref.25--34**2.360.00**1.334.1935--44**2.220.01**1.194.1345--541.900.090.913.9455+0.850.780.272.66 HIV test in last 12 months and knowing the resultnot testedref.tested and knowing the result**1.510.03**1.042.19 Number of partners with condomless anal intercourseno partnerref.1 partner0.850.500.541.352--3 partners1.280.300.812.034--5 partners1.350.390.682.696--10 partners1.560.250.743.29\> 10 partners**2.800.01**1.345.85 Type of drugs during last anal sexno use of sexual performance substances (poppers, erectile dysfunction medication)ref.sexual performance substances (poppers, erectile dysfunction medication)**1.910.00**1.322.76 \_cons*0.010.000.010.02* city*0.32--0.101.01*^a^the three models estimate associations in three groups:uHIVinc -- undiagnosed HIV in a group of men reporting a last negative HIV test result within the previous 12 monthsuHIVunk -- undiagnosed HIV in a group of men who never tested for HIV or whose last negative HIV test result is older than 12 monthsuHIV -- undiagnosed HIV in the combined group of men irrespective of the time of the last negative HIV test

Education, migration status, outness, frequency of visiting gay sex venues in the last 6 months, partnership status, type of partner for the last anal intercourse, condom use during last anal intercourse, and sexual role during last anal intercourse were not significantly different between men with and without undiagnosed HIV infection.

Discussion {#Sec11}
==========

Approximately one third of the study participants who were living with HIV and for whom their HIV status knowledge could be assessed were unaware of being infected. This is much higher than proportions reported from some modelling studies or estimates reported to ECDC for Dublin Declaration monitoring \[[@CR2], [@CR25], [@CR26]\]. This apparent contradiction is likely explained by an age related effect in our sample: as we can show in our analyses, the proportion of undiagnosed HIV is highly age-dependent. A large proportion of MSM living with HIV in the Western European countries, where the HIV epidemic amongst MSM started already in the 1980s, is already older than 40 years. These higher age groups are underrepresented among the visitors of gay venues that often cater to younger MSM clients. When the different age composition of the Sialon sample and the MSM population in modelling studies are considered, the results in terms of the proportions of undiagnosed infections are essentially comparable \[own unpublished comparisons between modelling results of the German undiagnosed fraction and Sialon results for Hamburg\]. Contrastingly, in Eastern European countries, where the HIV epidemic among MSM is more recent and the fraction of older infections in aging survivors is much smaller, the Sialon results are comparable with modelling studies \[[@CR27]\]. Another aspect that needs to be considered when comparing Sialon II results with national modelling studies is that Sialon II was conducted in large cities while modelling studies include whole countries. Regardless, our findings underline that in many settings where MSM congregate and seek sexual partners, a considerable proportion of those who are living with HIV are unaware of their HIV status.

Our analysis further shows that men with an undiagnosed HIV infection are a heterogeneous group of people. In our European multi-city sample, approximately two-third of those with undiagnosed HIV infection reported to have received a negative HIV test result in the previous 12 months, indicating the relatively recent acquisition of the infection and substantial incidence in this group. Moreover, this subgroup of men appears to test more frequently and be aware of risks. Taking this into account, the probability is high that many of them would have been tested again and diagnosed in the near future. It might also be that some of them tested in the HIV window period and received a false negative test result. To improve early HIV diagnosis in this group, men with these characteristics presenting for HIV testing should be offered laboratory testing with 4th generation HIV antigen/antibody tests to increase the probability to detect recent infections. If sufficient resources are available, even targeted PCR testing could be considered if this subgroup can be identified among the clients of the testing facilities, e.g. based on a combined symptoms and behaviours score \[[@CR28], [@CR29]\].

The men with undiagnosed infection following a negative test within the past 12 months had high odds of having used recreational drugs during their last anal sex encounter and high odds of not discussing their HIV status with the last anal sex partner(s) \[[@CR30]\]. Because viral load and transmissibility of HIV are very high during the phase of acute HIV infection \[[@CR31]--[@CR33]\], many of their recent sexual partners may have been at high risk for acquiring HIV infection if they engaged in condomless anal intercourse relying on an assumed negative HIV status. In the literature, the associations between repeat testing and risk behaviours are complex. Receiving a negative result may trigger different reactions from reassurance in safe practices to feeling lucky or invulnerable, or reinforce risky behaviour that is associated with a subsequent higher frequency of unprotected sex \[[@CR34]\].

These findings clearly point to the need of recommending more frequent testing in selected groups of MSM, especially to those using recreational drugs. More importantly, the testers could be considered as primary target group for HIV pre-exposure prophylaxis (PrEP) to avoid HIV infection in the first place, as also suggested by other authors \[[@CR35]\].

Approximately one-third of the men with undiagnosed HIV in the Sialon II sample infrequently test for HIV, although they tend to have multiple condomless anal sex encounters. Higher proportions were observed particularly in the four RDS cities, which may suggest that more hidden subgroups within the MSM populations were reached (see also Limitations). This, from a public health perspective, is an advantage of this sampling methodology compared to TLS method and probably to National HIV surveillance systems as well. While the study was not designed to answer the research question on identifying characteristics and behaviours of undiagnosed HIV-infected participants, only number of partners with whom condomless anal intercourse was practiced and more frequent STI testing was associated with the outcome variable (undiagnosed HIV infection) in this group. While age was significantly and independently associated with being undiagnosed in this group, more research will be necessary to characterize MSM living with undiagnosed HIV infection who do not test frequently for this infection in order to develop evidence-based interventions to increase test uptake. However, in the bivariate analysis we also found high odds for having been diagnosed with a STI during the last 12 months in this group. This strongly suggests that contrary to guidelines and recommendations HIV testing had not been offered or not been conducted in the context of these STI diagnoses. We are unable to determine whether this missed opportunity for an earlier diagnosis of HIV is related to a lack of discussion and disclosure of sexual orientation with the STI test and treatment provider or to a lack of compliance with testing guidelines by the STI treatment providers.

Partnership status and type of partner for last anal intercourse were not significantly associated with undiagnosed HIV, suggesting that condomless sex within steady partnerships may not always be as safe as people tend to assume, particularly if HIV status has not been checked mutually and/or if condomless anal sex is practiced concurrently with non-steady partners.

Limitations {#Sec12}
-----------

For correct interpretation of our findings it must be considered that we report on associations with undiagnosed HIV infections in a very specific group. Factors associated with undiagnosed HIV may partly be different from factors associated with transmission risk, because a part of those who acquire HIV will be diagnosed and detected early. For MSM who infrequently test for HIV it may be difficult to detect behavioural correlates for their infection risk because we asked for behaviours in the previous 6 months. The moment when these men acquired HIV may be longer ago and their behaviour may have changed. MSM who have never been tested for HIV may be underrepresented in our sample. Never tested MSM are often less integrated into gay communities and rarely visit gay venues; this explains why they would have a lower chance to be recruited in our study, at least when considering the cities where a TLS approach has been adopted to enrol study participants \[[@CR36]\]. This means that our uHIVunk group may mainly represent pattern 2 testing (triggered by health concerns not immediately related to acute HIV disease or transmission risk awareness) and less pattern 3 testing. A further limitation is that HIV status knowledge was based on self-reports and some participants may have felt uncomfortable reporting their HIV status in the questionnaire. Underreporting of a positive HIV status would have weakened any association we found between being undiagnosed and other factors.

Conclusions {#Sec13}
===========

Our study findings reinforce the recommendations for healthcare provider-initiated HIV testing when certain indicator diseases such as STIs are diagnosed. The findings may also inform community-based low-threshold HIV testing strategies such as home-collection sampling and test promotion campaigns to reduce the proportion of the hidden HIV epidemic. Such strategies should include certain elements of information (e.g. on the sensitivity of different tests during acute HIV infection), focus on interpersonal skills and community norms (e.g. communication with sexual partners about serostatus) and highlight additional risks associated with recreational drug use, while recognising the diversity of MSM with undiagnosed HIV across Europe. In addition, novel strategies such as home-testing should be discussed in the light of safeguarding linkage to care \[[@CR37]\]. Since data were collected in different European cities, the findings allow for a high degree of tailoring local prevention campaigns, i.e. developing targeted HIV and STI testing campaigns considering the local contexts in both community-based HIV testing and counselling and advice offered at such HIV testing sites \[[@CR38], [@CR39]\].

More importantly, tailored strategies based on the established HIV testing patterns should be embedded within an overall combined prevention approach \[[@CR40]\], which should include the addition of PrEP to the available effective prevention tools \[[@CR40]--[@CR42]\] for instance for those MSM reporting condomless anal sex with multiple partners in the last 6 months.
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AI

:   Anal intercourse

CD4

:   T-helper lymphocytes

CLIA

:   Chemoluminescence-Immunoassay

ECDC

:   European Centre for Disease Prevention and Control

ELISA

:   Enzyme Linked Immuno Sorbent Assay

EU

:   European Union

GHB

:   γ-hydroxybutric acid

HIV Ag/Ab

:   HIV Antigen/Antibody

HIV

:   Human Immunodeficiency Virus

IgG

:   Immunoglobulin G

MSM

:   Men having sex with men

nHIV

:   HIV-uninfected

OF

:   Oral fluid

pHIV

:   Previously diagnosed with HIV infection

PrEP

:   Pre-exposure prophylaxis

RDS

:   Respondent-driven-sampling

STI

:   Sexually transmitted infection

TLS

:   Time-location-sampling

uHIV

:   HIV-infected but as yet undiagnosed

uHIVinc

:   Incident HIV infection - negative test result reported within 12 months before the study specimen was collected

uHIVunk

:   HIV infection of unknown onset

UK

:   United Kingdom

WHO

:   World Health Organization

WHO-ERC

:   WHO Ethics Review Committee

WHO-RP2

:   WHO Research Project Review Panel
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